Foldable toric IOL safe and effective in high astigmatism

Article

According to Omid Kermani from the Augenabteilung der PAN-Klinik am Neumarkt, Köln, Germany, and colleagues, the implantation of a foldable toric intraocular lens (IOL) is a safe and predictable procedure for the correction of high pre-existing corneal astigmatism in cataract surgery.

According to Omid Kermani from the Augenabteilung der PAN-Klinik am Neumarkt, Köln, Germany, and colleagues, the implantation of a foldable toric intraocular lens (IOL) is a safe and predictable procedure for the correction of high pre-existing corneal astigmatism in cataract surgery.

A total of 58 eyes were implanted with the MS 6116 TU IOL (HumanOptics) lens during a retrospective study. The IOL has a 6 mm silicon optic with a toric rear surface and the PMMA-haptics are undulated with a Z-shaped design to prevent secondary rotation. Average preoperative astigmatism was 3.75 D.

Postoperatively, astigmatism was reduced to 0.84 D and surgically induced astigmatism was less than 0.5 D in all cases. 85% of the IOLs remained stable within 10° of the target axis. In 5% of the eyes, secondary rotation was performed three to six weeks postoperatively.

Kermani and his colleagues concluded that implantation of HumanOptics' foldable toric IOL is both safe and effective in treating high corneal astigmatism in cataract surgery.

Ophthalmology Times Europe reporting from the XXIV Congress of the ESCRS, London, 9-13 September, 2006.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.